OrphAI Therapeutics

OrphAI Therapeutics is a leading biotechnology research company dedicated to identifying and developing innovative therapeutics. Focused on addressing critical medical needs, OrphAI Therapeutics is committed to advancing healthcare through cutting-edge research and development. The company's current clinical-stage drug candidates target Group 1 and Group 3 Pulmonary Hypertension and bronchiolitis obliterans syndrome post lung transplant, showcasing its dedication to pioneering solutions in these areas.

Located at 101 College Street, New Haven, 06510, US, OrphAI Therapeutics is driven by a vision to improve patient outcomes through targeted and effective therapies. By leveraging molecular and cell biology, the company is at the forefront of clinical development, striving to bring novel treatments to market.

OrphAI Therapeutics continues to expand its research and development efforts, reinforcing its position as a key player in the biotechnology sector. We invite the management of OrphAI Therapeutics to create a customized and exclusive company showcase and product listing on our platform to further enhance your company's visibility and commercial development.